IDXX Relative Valuation
IDXX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IDXX is overvalued; if below, it's undervalued.
Historical Valuation
IDEXX Laboratories Inc (IDXX) is now in the Fair zone, suggesting that its current forward PE ratio of 41.39 is considered Fairly compared with the five-year average of 52.30. The fair price of IDEXX Laboratories Inc (IDXX) is between 470.68 to 712.94 according to relative valuation methord.
Relative Value
Fair Zone
470.68-712.94
Current Price：501.57
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
28.89
P/B
Median3y
39.73
Median5y
58.08
2.03
FCF Yield
Median3y
1.72
Median5y
1.55
Competitors Valuation Multiple
The average P/S ratio for IDXX's competitors is 6.19, providing a benchmark for relative valuation. IDEXX Laboratories Inc Corp (IDXX) exhibits a P/S ratio of 9.89, which is 59.90% above the industry average. Given its robust revenue growth of 3.56%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is IDEXX Laboratories Inc (IDXX) currently overvalued or undervalued?
What is IDEXX Laboratories Inc (IDXX) fair value?
How does IDXX's valuation metrics compare to the industry average?
What is the current P/B ratio for IDEXX Laboratories Inc (IDXX) as of May 24 2025?
What is the current FCF Yield for IDEXX Laboratories Inc (IDXX) as of May 24 2025?
What is the current Forward P/E ratio for IDEXX Laboratories Inc (IDXX) as of May 24 2025?